Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety and efficacy of combination therapy with Sandostatin LAR plus pegvisomant will be compared with that of Sandostatin LAR alone or pegvisomant alone in patients with active acromegaly. The primary endpoint is to determine the number of patients in each group who experience adverse events and the nature of the adverse events. Secondary endpoints of efficacy include the number of patients who achieve a normal serum IGF-1 concentration, clinical improvement (ring size, acromegaly signs and symptom scale) and quality of life scores. This is a multi-center, open-label, parallel group, partially randomized, pegvisomant dose optimization study.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000847-33
Application #
7374430
Study Section
Special Emphasis Panel (ZRR1-CR-8 (01))
Project Start
2006-05-05
Project End
2007-02-28
Budget Start
2006-05-05
Budget End
2007-02-28
Support Year
33
Fiscal Year
2006
Total Cost
$10,723
Indirect Cost

  Institution

Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904

  Publications

Campbell, Garland A; Patrie, James T; Gaylinn, Bruce D et al. (2018) Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrol Dial Transplant 33:523-530
Malin, Steven K; Rynders, Corey A; Weltman, Judy Y et al. (2016) Endothelial function following glucose ingestion in adults with prediabetes: Role of exercise intensity. Obesity (Silver Spring) 24:1515-21
Rynders, Corey A; Weltman, Judy Y; Malin, Steven K et al. (2016) Comparing Simple Insulin Sensitivity Indices to the Oral Minimal Model Postexercise. Med Sci Sports Exerc 48:66-72
Hu, Yinin; Kim, Helen; Blackwell, Christopher M et al. (2015) Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 262:456-64; discussion 462-4
Marozkina, Nadzeya V; Wang, Xin-Qun; Stsiapura, Vitali et al. (2015) Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. Eur Respir J 45:87-97
Nass, Ralf; Nikolayev, Alexander; Liu, Jianhua et al. (2015) The level of circulating octanoate does not predict ghrelin O-acyl transferase (GOAT)-mediated acylation of ghrelin during fasting. J Clin Endocrinol Metab 100:E110-3
Argo, Curtis K; Patrie, James T; Lackner, Carolin et al. (2015) Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 62:190-7
Chyun, Deborah A; Wackers, Frans J Th; Inzucchi, Silvio E et al. (2015) Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Med 3:2050312114568476
Nass, Ralf; Farhy, Leon S; Liu, Jianhua et al. (2014) Age-dependent decline in acyl-ghrelin concentrations and reduced association of acyl-ghrelin and growth hormone in healthy older adults. J Clin Endocrinol Metab 99:602-8
Hu, Yinin; Petroni, Gina R; Olson, Walter C et al. (2014) Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 63:779-86

Showing the most recent 10 out of 674 publications